MoFo Advises Krystal Biotech on $45.5 M IPO

09/22/2017

John W. Campbell III and Emiko Kurotsu

Corporate and Emerging Companies + Venture Capital

MoFo News Item

Morrison & Foerster LLP advised Krystal Biotech, Inc. on its initial public offering of 4,554,000 shares of common stock at a price of $10.00 per share, which includes 594,000 shares of common stock exercised pursuant to the underwriter’s over-allotment option. Aggregate gross proceeds to the company were $45,540,000, before underwriting discounts, commissions and expenses. The stock is listed on the NASDAQ Capital Market (NASDAQ) under the symbol “KRYS”. The offering closed on September 22, 2017.

Founded in San Francisco and based in Pittsburgh, PA, Krystal Biotech is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases.

The MoFo team advising Krystal is led by San Francisco-based corporate partner John Campbell and includes corporate associates Emiko Kurotsu (Palo Alto) and Katherine Shaia (Washington, D.C.).

Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with the offering.

See the related press release.

Select media coverage:

  • Daily Journal: “Dealmakers” (September 26, 2017)
  • Pittsburgh Business Times: “Krystal Biotech Completes IPO” (September 22, 2017)
  • Law360: “Alibaba-Backed Best Leads 5 IPOs Raising Nearly $1B” (September 20, 2017 - reprinted with permission)

Email Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

©1996-2017 Morrison & Foerster LLP. All rights reserved.